|
|
| Product Name: | H 835 | | Synonyms: | 1H-Purine-2,6-dione, 3,7-dihydro-7-(2-(((1S,2R)-2-hydroxy-1-methyl-2-phenylethyl)amino)ethyl)-1,3-dimethyl-, monohydrochloride, mixt. with 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride;3,7-Dihydro-7-(2-(((1S,2R)-2-hydroxy-1-methyl-2-phenylethyl)amino)ethyl)-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride, mixt. with 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride;Acrinor;Decrinor;H 835 | | CAS: | 8004-31-7 | | MF: | C35H46Cl2N10O8 | | MW: | 805.72 | | EINECS: | | | Product Categories: | | | Mol File: | 8004-31-7.mol |  |
| | H 835 Chemical Properties |
| | H 835 Usage And Synthesis |
| Description | Acrinor is a adrenergic beta receptor agonist. | | Uses | Cafedrine-theodrenaline can stimulate the cardiovascular system through β-adrenergic receptor mediation, increasing arterial pressure, stroke volume, and cardiac output, while reducing peripheral vascular resistance, thereby supporting overall cardiac function. Cafedrine-theodrenaline helps maintain blood pressure during hypotensive episodes without causing significant tachycardia[1]. | | IC 50 | β-adrenoceptor | | References | [1] Sternitzke N, et al. Effect of Akrinor on cardiovascular-dynamics before and after blockade of adrenergic beta-receptors by propranolol[J]. Zeitschrift fur Kardiologie, 1975, 64(5): 419-430. PMID:1189536 |
| | H 835 Preparation Products And Raw materials |
|